Summary

Asgard Therapeutics unites a rising group of specialists across cell reprogramming, gene therapy, and immuno-oncology disciplines. This collective expertise drives their goal to create groundbreaking, readily available gene therapies centered around their principal development, AT-108.

The initiative has secured substantial financial backing through various prestigious programs. Funding sources include the Eurostars-2 joint program, supported by EUREKA member nations and the European Union's Horizon 2020 Framework Programme. Additionally, the project received support from the EIC Women in Tech program, utilizing funds from the Horizon Europe program.

Title

Developing a cancer immunotherapy based on direct cell reprogramming - ASGARD THERAPEUTICS

Description

Developing a cancer immunotherapy based on direct cell reprogramming - ASGARD THERAPEUTICS

Keywords

asgard, cell, team, therapeutics, cancer, gene, news, immunotherapy, program, science, publications, therapy, lead, shelf, european, union, careers

Downstreams

linkedin.com, twitter.com, sciencedirect.com

NS Lookup

A 185.15.121.100

Dates

Created 2026-10-12

Updated 2026-10-15

Summarized 2026-10-15